VCYT Veracyte Inc

Price (delayed)

$42.6

Market cap

$3.42B

P/E Ratio

29.58

Dividend/share

N/A

EPS

$1.44

Enterprise value

$3.16B

?
Relative Growth: Rel. Growth: 89
Relative Strength: Rel. Strength: 62
Relative Valuation: Rel. Valuation: 61
Relative Profitability: Rel. Profitability: 94

Veracyte is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide ...

Highlights
The company's quick ratio has surged by 77% YoY
The stock's price to earnings (P/E) is 43% less than its last 4 quarters average of 52.0

Key stats

What are the main financial stats of VCYT

VCYT stock price

How has the Veracyte stock price performed over time
Intraday
-4.66%
1 week
-7.69%
1 month
-25.89%
1 year
38.85%
YTD
1.19%
QTD
-27.46%

Financial performance

How have Veracyte's revenue and profit performed over time
Revenue
$561.9M
Gross profit
$402.96M
Operating income
$105.77M
Net income
$114.48M
Gross margin
71.7%
Net margin
20.4%
The operating income has grown by 36% from the previous quarter
The operating margin has grown by 31% from the previous quarter
Veracyte's net income has increased by 30% QoQ
The net margin has grown by 26% from the previous quarter

Price vs fundamentals

How does VCYT's price correlate with its fundamentals

Growth

What is Veracyte's growth rate over time

Valuation

What is Veracyte stock price valuation
P/E
29.58
P/B
2.45
P/S
6.06
EV/EBIT
27.27
EV/EBITDA
22.65
EV/Sales
5.63
The stock's price to earnings (P/E) is 43% less than its last 4 quarters average of 52.0
The EPS has increased by 30% since the previous quarter
The P/B is 23% above the 5-year quarterly average of 2.0 but 2% below the last 4 quarters average of 2.5
The equity has grown by 14% YoY and by 3.3% from the previous quarter
Veracyte's revenue has increased by 17% YoY and by 3.7% QoQ
The P/S is 7% below the 5-year quarterly average of 6.5 and 2.3% below the last 4 quarters average of 6.2

Efficiency

How efficient is Veracyte business performance
The ROA has grown by 27% from the previous quarter
The company's return on equity rose by 25% QoQ
The return on sales has increased by 23% since the previous quarter
VCYT's return on invested capital is up by 16% since the previous quarter

Dividends

What is VCYT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VCYT.

Financial health

How did Veracyte financials performed over time
The company's quick ratio has surged by 77% YoY
The company's current ratio has surged by 69% YoY
The debt is 97% less than the equity
VCYT's debt to equity is down by 25% year-on-year
The debt has contracted by 21% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.